2Q EARNINGS: Vivus's Qsymia sales miss; Orexigen plans US, EU Contrave filings
This article was originally published in Scrip
Executive Summary
Vivus reported relatively slow growth for second quarter sales of its obesity therapy Qsymia (phentermine and topiramate) on 6 August while future competitor Orexigen Therapeutics said it soon will file for approval of its weight loss drug Contrave (naltrexone and bupropion) in the EU where Qsymia's approval has been denied twice.